17-Jul-2026
Goldman Sachs Keeps Their Sell Rating on Bruker (BRKR)
TipRanks (Wed, 15-Jul 4:37 PM ET)
Business Wire (Wed, 15-Jul 7:00 AM ET)
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
Business Wire (Thu, 4-Jun 7:00 AM ET)
Business Wire (Tue, 2-Jun 11:24 AM ET)
Business Wire (Mon, 1-Jun 7:00 AM ET)
Business Wire (Tue, 26-May 7:00 AM ET)
Market Chameleon (Wed, 6-May 5:10 AM ET)
Bruker Reports First Quarter 2026 Financial Results
Business Wire (Wed, 6-May 6:30 AM ET)
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
Business Wire (Fri, 24-Apr 7:00 AM ET)
Industry Veteran Jack Phillips Joins Bruker Board as Company Expands Diagnostics Portfolio
Market Chameleon (Mon, 8-Dec 3:26 AM ET)
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Bruker trades on the NASDAQ stock market under the symbol BRKR.
As of July 17, 2026, BRKR stock price declined to $58.23 with 2,214,535 million shares trading.
BRKR has a beta of 1.66, meaning it tends to be more sensitive to market movements. BRKR has a correlation of 0.10 to the broad based SPY ETF.
BRKR has a market cap of $8.86 billion. This is considered a Mid Cap stock.
Last quarter Bruker reported $823 million in Revenue and $.31 earnings per share. This beat revenue expectation by $27 million and exceeded earnings estimates by $.08.
In the last 3 years, BRKR traded as high as $94.86 and as low as $28.53.
The top ETF exchange traded funds that BRKR belongs to (by Net Assets): IJH, VTI, VB, FBT, VBR.
BRKR has outperformed the market in the last year with a return of +38.5%, while the SPY ETF gained +19.5%. In the last 3 month period, BRKR beat the market returning +43.2%, while SPY returned +4.9%. However, in the most recent 2 weeks BRKR has underperformed the stock market by returning -5.5%, while SPY returned -0.2%.
BRKR support price is $57.50 and resistance is $61.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BRKR shares will trade within this expected range on the day.